Physician profile
Drew E Rowan
NPI 1285079384
$1,750.69
in general payments reported to CMS, 2019-2025
27 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $193 · 2021: $171 · 2022: $17.08 · 2023: $102 · 2024: $141 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $590.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $213.00 | 2019-2025 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $210.49 | 2019-2024 | Airsupra |
| Abbvie INC. | $181.96 | 2019-2025 | Vraylar |
| Pfizer INC. | $120.72 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $93.00 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.38 | 2019-2021 | |
| Amarin Pharma, INC. | $88.14 | 2019-2020 | |
| Lilly USA, LLC | $86.02 | 2019-2021 | |
| Janssen Biotech, INC. | $78.61 | 2025 | Stelara, Simponi, Simponi Aria |
| Glaxosmithkline, LLC. | $69.18 | 2019-2025 | Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $62.15 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $56.45 | 2019-2024 | Eliquis |
| Astellas Pharma US INC | $50.85 | 2021-2025 | Veozah |
| Abbott Laboratories | $45.81 | 2024-2025 | Freestyle Libre 3 |
| Sage Therapeutics, LLC | $36.16 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.11 | 2025 | Caplyta |
| Amgen INC. | $34.04 | 2019-2025 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $27.82 | 2019 | |
| Lundbeck LLC | $24.76 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $24.35 | 2024 | Voquezna |
| Genentech USA, INC. | $22.55 | 2019 | |
| Inspire Medical Systems, INC. | $18.97 | 2024 | Inspire |
| Boston Scientific Corporation | $18.80 | 2021 | |
| Sanofi Pasteur INC. | $17.56 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $16.62 | 2020 | |
| Dexcom, INC. | $15.98 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Rowan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.